Leerink Partners Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $6.00

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) had its price objective reduced by research analysts at Leerink Partners from $7.00 to $6.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a "market perform" rating on the stock. Leerink Partners' target price points to a potential downside of 8.88% from the stock's current price.

A number of other brokerages also recently commented on RXRX. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $8.25.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded down $0.01 during mid-day trading on Friday, hitting $6.59. The stock had a trading volume of 23,912,131 shares, compared to its average volume of 26,028,189. The firm's 50 day moving average is $7.71 and its 200 day moving average is $7.09. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of -4.35 and a beta of 0.86. Recursion Pharmaceuticals has a twelve month low of $5.60 and a twelve month high of $12.48.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business's quarterly revenue was down 57.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.42) earnings per share. Equities research analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals during the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter worth about $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $27,000. GAMMA Investing LLC boosted its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after buying an additional 4,948 shares during the period. Finally, Farther Finance Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after buying an additional 4,091 shares during the period. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.